XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 19 - Segment Reporting
 6 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

Note 19 - Segment Reporting

 

The Company’s chief operating decision maker (“CODM”), who is the Company’s Chief Executive Officer, allocates resources and assesses performance based on the Company’s financial information. The CODM reviews financial information presented for each reportable segment for the purpose of making operating decisions and assessing financial performance.

 

The Company manages and aggregates its operational and financial information in accordance with two reportable segments: Rx and Consumer Health. The Rx Segment consists of the Company’s prescription products. The Consumer Health Segment contains the Company’s consumer healthcare products. For purposes of determining operating income or loss by segment, the Company allocates common expenses such as corporate administration, executive and board compensation, insurance, and fees associated with being a publicly traded entity, among others, to the Rx Segment. The Rx Segment also includes pipeline research and development. The CODM does not regularly review asset information by segment, accordingly, asset information is not provided by segment.

 

Select financial information for these segments is as follows:

 

  

Rx

  

Consumer Health

  

Consolidated

 
  

(in thousands)

 

Three Months Ended December 31, 2023

            
             

Product revenue, net

 $18,748  $4,186  $22,934 

Income (loss) from operations

 $3,146  $(782) $2,364 
             

Depreciation and amortization

 $1,510  $389  $1,899 

Stock-based compensation expense

 $707  $113  $820 
             

Three Months Ended December 31, 2022

            
             

Product revenue, net

 $18,029  $8,250  $26,279 

Loss from operations

 $(5,464) $(1,404) $(6,868)
             

Depreciation and amortization

 $1,572  $281  $1,853 

Impairment expense

 $2,600  $—  $2,600 

Stock-based compensation expense

 $2,987  $80  $3,067 

 

  

Rx

  

Consumer Health

  

Consolidated

 
  

(in thousands)

 

Six Months Ended December 31, 2023

            
             

Product revenue, net

 $36,565  $8,468  $45,033 

Income (loss) from operations

 $2,280  $(1,420) $860 
             

Depreciation and amortization

 $3,064  $776  $3,840 

Stock-based compensation expense

 $1,432  $318  $1,750 
             

Six Months Ended December 31, 2022

            
             

Product revenue, net

 $36,681  $17,253  $53,934 

Loss from operations

 $(6,457) $(2,219) $(8,676)
             

Depreciation and amortization

 $3,146  $562  $3,708 

Impairment expense

 $2,600  $—  $2,600 

Stock-based compensation expense

 $4,149  $95  $4,244